Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.
Aaron Seth Rosenberg, MD, MS, associate professor, Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health, discusses the potential clinical implications of the phase 2 GRIFFIN trial (NCT02874742) in multiple myeloma.
Initial findings from the GRIFFIN trial demonstrated improved efficacy with the combination of daratumumab (Darzalex), lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) followed by daratumumab maintenance vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma.
Although the data remain immature, the findings from the GRIFFIN trial have changed frontline treatment for some patients with transplant-eligible multiple myeloma, Rosenberg says. Providers interested in the early adoption of a quadruplet-based regimen may be comfortable this approach given the available data from the study, Rosenberg adds.